A shareholder has filed a class action lawsuit against Aardvark Therapeutics, alleging the company made false and misleading statements about its business and financial health. These alleged misrepresentations caused Aardvark's stock to trade at inflated prices from its IPO in February 2025 through May 2026. The lawsuit claims investors suffered significant losses when the truth emerged. Investors interested in joining the lawsuit or serving as lead plaintiff must act by October 13, 2026.
Mastercard CEO Michael Miebach revealed plans to expand beyond traditional credit card payments by focusing on AI shopping agents and a new category of machine-to-machine payments for digital goods like compute power and data. The company introduced ...
Bernstein Liebhard LLP is investigating whether certain directors and officers of Badger Meter, Inc. breached their fiduciary duties to shareholders. The law firm aims to determine if the company's leadership acted in shareholders' best interests and...
Bernstein Liebhard LLP is investigating whether certain directors and officers of Erasca, Inc. breached their fiduciary duties to the company and its shareholders. The probe aims to determine if the leadership acted in shareholders' best interests an...
Bernstein Liebhard LLP is investigating whether certain directors and officers of Gartner, Inc. breached their fiduciary duties to the company and its shareholders. The investigation aims to determine if the leadership acted in shareholders' best int...
Bernstein Liebhard LLP is investigating whether certain directors and officers of Calix, Inc. breached their fiduciary duties to the company and its shareholders. The investigation aims to determine if Calix's leadership acted in shareholders' best i...
